<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614574</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-GCB-087</org_study_id>
    <nct_id>NCT01614574</nct_id>
  </id_info>
  <brief_title>Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease</brief_title>
  <official_title>A Multicenter, Open-Label Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB)&#xD;
      that leads to progressive accumulation of glucocerebroside within macrophages and subsequent&#xD;
      tissue and organ damage; typically of the liver, spleen, bone marrow, and brain. The disease&#xD;
      has been classified into 3 clinical subtypes based on the presence or absence of neurological&#xD;
      symptoms and severity of neurological disease. Type 1 Gaucher disease affects an estimated&#xD;
      30,000 persons worldwide and is the most common. Type 1 Gaucher disease does not involve the&#xD;
      central nervous system. Patients with type 2 Gaucher disease present with acute neurological&#xD;
      deterioration, which leads to early death. Those with type 3 disease typically display a more&#xD;
      sub-acute neurological course, with later onset and slower progression.&#xD;
&#xD;
      The primary objective of this study is to evaluate the safety of every other week dosing of&#xD;
      velaglucerase alfa in Japanese patients with Gaucher disease.&#xD;
&#xD;
      Velaglucerase alfa has been developed and approved as an enzyme replacement therapy for Type&#xD;
      1 Gaucher disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB)&#xD;
      that leads to progressive accumulation of glucocerebroside within macrophages and subsequent&#xD;
      tissue and organ damage; typically of the liver, spleen, bone marrow, and brain.&#xD;
&#xD;
      Gaucher disease has been designated in the list of Specified Rare and Intractable Diseases by&#xD;
      Specified Disease Treatment Research Program of Ministry of Health, Labor and Welfare (MHLW)&#xD;
      as one of &quot;lysosomal storage diseases&quot; since 2001. Gaucher disease is also designated in the&#xD;
      Medical Aid Program for Specified Categories of Chronic Pediatric Diseases.&#xD;
&#xD;
      The prevalence of mutations and the phenotype of patients with Gaucher disease in Japan&#xD;
      differs from that in non-Japanese populations. Some patients with type 1 Gaucher disease in&#xD;
      Japan have more severe and progressive disease compared to non-Japanese patients and the&#xD;
      disease is characterized by an earlier onset of symptoms.&#xD;
&#xD;
      Velaglucerase alfa, a highly-purified form of the naturally occurring enzyme&#xD;
      glucocerebrosidase, has been developed as an enzyme replacement therapy for Gaucher disease&#xD;
      for the symptoms (anemia, thrombocytopenia, hepatomegaly, splenomegaly, and bone&#xD;
      manifestation).&#xD;
&#xD;
      The primary objective of this study is to evaluate the safety of every other week dosing of&#xD;
      velaglucerase alfa in Japanese patients (naive or previously treated with imiglucerase) 2&#xD;
      years of age and older with Gaucher disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2012</start_date>
  <completion_date type="Actual">May 25, 2013</completion_date>
  <primary_completion_date type="Actual">May 25, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Severe Adverse Events (SAE)</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of Anti-velaglucerase Alfa Antibody</measure>
    <time_frame>Baseline to week51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infusion- Related Adverse Events</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Concomitant Medication</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin Concentration</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Count</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Liver Volume, Normalized to Body Weight</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spleen Volume, Normalized to Body Weight</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Chitotriosidase Levels</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CCL18 Levels</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>velaglucerase alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>velaglucerase alfa</intervention_name>
    <description>60 U/kg every other week intravenous infusion</description>
    <arm_group_label>Investigational</arm_group_label>
    <other_name>VPRIV</other_name>
    <other_name>Gene activated human glucocerebrosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has a documented diagnosis of Gaucher disease&#xD;
&#xD;
          -  The patient is at least 2 years of age&#xD;
&#xD;
          -  Female patients of child bearing potential must agree to use a medically acceptable&#xD;
             method of contraception at all times during the study&#xD;
&#xD;
          -  The patient, the patient's parent(s) or legal guardian(s) has provided written&#xD;
             informed consent that has been approved by the Institutional Review Board/Independent&#xD;
             Ethics Committee (IRB/IEC)&#xD;
&#xD;
          -  The patient must be sufficiently cooperative to participate in this clinical study as&#xD;
             judged by the Investigator&#xD;
&#xD;
        Patients who are switched from imiglucerase ERT must meet the following additional&#xD;
        criteria:&#xD;
&#xD;
          -  Received treatment with imiglucerase for a minimum of 12 consecutive months&#xD;
&#xD;
          -  Meet predefined limits for hemoglobin concentration and platelet counts&#xD;
&#xD;
        Patients na√Øve to treatment for Gaucher disease must meet the following additional&#xD;
        criteria:&#xD;
&#xD;
          -  Not received treatment for Gaucher disease (investigational or approved products)&#xD;
             within 12 months prior to study entry&#xD;
&#xD;
          -  Have Gaucher disease related anemia and at least one of the following: moderate&#xD;
             splenomegaly or, Gaucher disease-related thrombocytopenia or Gaucher disease-related&#xD;
             enlarged liver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any investigational drug or device within the 30 days prior to study&#xD;
             entry (time of informed consent); such use during the study is not permitted&#xD;
&#xD;
          -  Positive for hepatitis B or hepatitis C.&#xD;
&#xD;
          -  Non-Gaucher disease related anemia&#xD;
&#xD;
          -  The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to&#xD;
             understand the nature, scope, and possible consequences of the study&#xD;
&#xD;
          -  Significant comorbidity, as determined by the Investigator that might affect study&#xD;
             data or confound the study results&#xD;
&#xD;
          -  The patient is unable to comply with the protocol or is unlikely to complete the&#xD;
             study, as determined by the Investigator&#xD;
&#xD;
          -  The patient has experienced a severe (grade 3 or higher) infusion-related&#xD;
             hypersensitivity reaction (anaphylactic or anaphylactoid reaction) to any ERT&#xD;
             (approved or investigational)&#xD;
&#xD;
          -  Currently receiving red blood cell growth factor, (eg, erythropoietin) or chronic&#xD;
             systemic corticosteroids in the last 6 months&#xD;
&#xD;
          -  Patient has had a splenectomy or the patient has an active, clinically significant&#xD;
             spleen infarction within 12 months of screening&#xD;
&#xD;
          -  Patient has worsening bone necrosis within 12 months of screening&#xD;
&#xD;
          -  The patient is pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University School of Medicine</name>
      <address>
        <city>Minato-ku</city>
        <state>Toyko</state>
        <zip>105-8461</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>July 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VPRIV¬Æ (15-60 U/kg)</title>
          <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VPRIV¬Æ (15-60 U/kg)</title>
          <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>JAPAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin Concentration</title>
          <units>(g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.77" spread="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet Count</title>
          <units>(x 10^9 platelets/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182.9" spread="32.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normalized liver volume</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.92" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normalized spleen volume</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.39" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma chitotriosidase</title>
          <units>(nmol/mL/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1243.7" spread="344.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CCL18 levels</title>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134.8" spread="132.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Severe Adverse Events (SAE)</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Severe Adverse Events (SAE)</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Emergent Adverse Events (TEAE)</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Adverse Events (TEAE)</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Development of Anti-velaglucerase Alfa Antibody</title>
        <time_frame>Baseline to week51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Anti-velaglucerase Alfa Antibody</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (Week 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (Week 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infusion- Related Adverse Events</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusion- Related Adverse Events</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Concomitant Medication</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Concomitant Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin Concentration</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Concentration</title>
          <units>(g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Count</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Count</title>
          <units>(x 10^9 platelets/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="35.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Liver Volume, Normalized to Body Weight</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Liver Volume, Normalized to Body Weight</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Spleen Volume, Normalized to Body Weight</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Spleen Volume, Normalized to Body Weight</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Chitotriosidase Levels</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Chitotriosidase Levels</title>
          <units>(nmol/mL/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.3" spread="64.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CCL18 Levels</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
            <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CCL18 Levels</title>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VPRIV¬Æ (15-60 U/kg)</title>
          <description>Administered as an intravenous (IV) infusion over a 60 minute period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINOPATHY PROLIFERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CHEILITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SUBMANDIBULAR MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HAND-FOOT-AND-MOUTH DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HORDEOLUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>JOINT SPRAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MYOCLONUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENSTRUATION IRREGULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ‚â§180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All 6 enrolled patients received previous long-term treatment with the enzyme replacement therapy (ERT), imiglucerase. Key therapeutic parameters were expected to indicate stability after switching from imiglucerase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

